💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Afatinib

CHEMBL1173655 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
37 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
485.9 g/mol
LogP
3.6
Phase
4

A targeted cancer medicine that blocks certain proteins called EGFR and HER2 that drive the growth of some cancers. By permanently binding to and shutting down these signaling proteins, afatinib helps slow or stop tumor growth in cancers where these targets are overactive.

น้ำหนักโมเลกุล

485.9400 g/mol

LogP

3.60

TPSA

88.60 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Endometriosis Cardiovascular Disease Respiratory Disease Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Infectious Disease Melanoma Gastroesophageal Reflux Disease Inflammatory Bowel Disease Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Lymphoma Breast Cancer Prostate Cancer Colorectal Cancer Leukemia

หมวดหมู่ยา

L — L - Antineoplastic and Immunomodulating Agents

กลไกการออกฤทธิ์

Irreversible covalent inhibitor of ErbB family (EGFR/HER1, HER2, HER4) tyrosine kinases.

Pharmacokinetics (PK)

Half-Life 37 hours

Pharmacodynamics (PD)

กลไก

Irreversible covalent inhibitor of ErbB family (EGFR/HER1, HER2, HER4) tyrosine kinases.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1

                

                

                
                

                    
InChI

                    
InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C24H25ClFN5O3

                    

                    
                    

                        
HBD / HBA

                        
2 / 8

                    

                    
                    

                        
พันธะที่หมุนได้

                        
8

                    

                    
                    
                    

                        
อะตอมหนัก

                        
34

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
คำถามที่พบบ่อย

                

                    
                    

                        
                        

                            
A targeted cancer medicine that blocks certain proteins called EGFR and HER2 that drive the growth of some cancers. By permanently binding to and shutting down these signaling proteins, afatinib helps slow or stop tumor growth in cancers where these targets are overactive.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Irreversible covalent inhibitor of ErbB family (EGFR/HER1, HER2, HER4) tyrosine kinases.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Afatinib: Half-life: 37 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Afatinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Methotrexate
                            Small molecule
                        
                        
                        
                            Tamoxifen
                            Small molecule
                        
                        
                        
                            Cyclosporine
                            Protein
                        
                        
                        
                            Tacrolimus
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1173655.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 10184653.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
ข้อจำกัดความรับผิดชอบทางการแพทย์

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.